Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 6, Pages 653-660
Publisher
Informa UK Limited
Online
2016-03-25
DOI
10.1586/14737140.2016.1170596
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value
- (2016) Christophe Deben et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
- (2015) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Reck et al. ANNALS OF ONCOLOGY
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
- (2014) Antonio Rossi et al. LANCET ONCOLOGY
- Platinum compounds in children with cancer
- (2013) Antonio Ruggiero et al. ANTI-CANCER DRUGS
- Cancer and Age: General Considerations
- (2012) Sarah Hoffe et al. CLINICS IN GERIATRIC MEDICINE
- ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis
- (2012) Jingwei Jiang et al. MOLECULAR BIOLOGY REPORTS
- Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2011) Joshua A. Roth et al. Clinical Lung Cancer
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2011) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations
- (2011) Richard A. Hubner et al. PLoS One
- The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making
- (2010) A. Rossi et al. CURRENT MEDICINAL CHEMISTRY
- American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
- (2010) J. Douglas Rizzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
- (2009) Yu Yang Soon et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2009) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
- (2008) João Paulo da Silveira Nogueira Lima et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started